All In Biotech

Drug Trial Radar · NCT03972150

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

An Open Label, Phase I Study of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI 754091 in Japanese Patients With Advanced Solid Tumours

Last checked: Nov 20, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Jun 12, 2019

Primary completion

Oct 27, 2020

Study completion Mar 28, 2022

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is: Part I * To determine Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836880 monotherapy Part II * To determine MTD and/or RP2D of the combination therapy of BI 836880 and BI 754091 The secondary objectives are: Part I * To document the safety and tolerability, and characterise pharmacokinetics (PK) of BI 836880 as monotherapy Part II * To document the safety and tolerability, and characterise PK of the combination therapy of BI 836880 and BI 754091

Conditions

  • Neoplasms

Interventions

  • BI 836880Drug

    Solution for infusion

  • BI 754091Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI754091Time frame: First treatment cycle, the first 21 days following the start of trial medication.
  2. Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment CycleTime frame: First treatment cycle, the first 21 days following the start of trial medication.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.